Drug Price Trends for NDC 72888-0117

Average Pharmacy Cost for 72888-0117

Drug Name	NDC	Price/Unit ($)	Unit	Date
GLIPIZIDE 10 MG TABLET	72888-0117-05	0.04633	EACH	2026-03-18
GLIPIZIDE 10 MG TABLET	72888-0117-01	0.04633	EACH	2026-03-18
GLIPIZIDE 10 MG TABLET	72888-0117-00	0.04633	EACH	2026-03-18

Best Wholesale Price for NDC 72888-0117

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for Ndc: 72888-0117

Last updated: February 19, 2026

Ndc: 72888-0117, a pharmaceutical product, faces a dynamic market influenced by patent expiry, generic competition, and evolving therapeutic landscapes. Projections indicate a decline in brand-name pricing post-patent expiration, with generic alternatives capturing significant market share.

What is Ndc: 72888-0117 and its Current Market Position?

Ndc: 72888-0117 is identified as a specific pharmaceutical product, though detailed public information regarding its active pharmaceutical ingredient (API), therapeutic class, and specific indications is not readily available in the public domain, often due to proprietary information or the product being a component of a larger formulation. The National Drug Code (NDC) is a unique 10- or 11-digit identifier assigned to each medication. For Ndc: 72888-0117, this code identifies a specific manufacturer, the drug's strength, dosage form, and package size.

Market data for specific NDC codes can be challenging to access without specialized subscription services. However, the general market position of any drug is determined by factors such as its approved indications, the prevalence of the diseases it treats, its efficacy and safety profile compared to existing treatments, and its reimbursement status by payers. Drugs with significant unmet medical needs or superior efficacy often command higher market shares and pricing. Conversely, those facing competition from numerous generics or newer, more effective therapies typically experience market erosion.

The primary source for understanding the market for a specific drug formulation identified by an NDC is through data from pharmaceutical market research firms, prescription volume data, and payer formulary listings. Without access to this proprietary data, a precise quantitative assessment of Ndc: 72888-0117's current market position is limited to inferential analysis based on general pharmaceutical market trends.

What is the Patent Landscape for Ndc: 72888-0117?

The patent landscape is a critical determinant of market exclusivity and pricing power for pharmaceutical products. For a drug identified by Ndc: 72888-0117, understanding its patent protection involves identifying patents covering the active pharmaceutical ingredient (API), specific formulations, manufacturing processes, and methods of use.

As of the most recent publicly accessible patent databases and regulatory filings, specific patent details for a drug solely identified by an NDC code are not directly searchable. The NDC code itself is not a patent identifier. To ascertain the patent status, one would typically need to identify the brand name of the drug or the name of the API associated with the NDC.

However, if Ndc: 72888-0117 represents a branded pharmaceutical product with a known API, the patent situation would involve:

• Composition of Matter Patents: These are the strongest patents, covering the API itself. They typically have a lifespan of 20 years from the filing date.
• Formulation Patents: These patents cover specific ways the API is delivered (e.g., extended-release tablets, injectables).
• Method of Use Patents: These patents cover the use of the drug for a specific medical condition.
• Patent Term Extensions (PTEs): These can extend patent protection to compensate for regulatory review delays.
• Exclusivity Periods: Beyond patents, regulatory exclusivities (e.g., New Chemical Entity (NCE) exclusivity, orphan drug exclusivity) provide market protection.

Without knowing the specific drug associated with Ndc: 72888-0117, a detailed patent analysis cannot be provided. However, the general principle is that the expiry of key composition of matter and formulation patents opens the door for generic manufacturers. The timeline of these patent expiries dictates the period of market exclusivity and the subsequent entry of competition.

For example, if Ndc: 72888-0117 is a product whose primary patents expired on January 1, 2023, then generic versions could have entered the market as early as that date, assuming they received FDA approval. If patents are still active and robust, market exclusivity would continue.

What are the Projected Market Dynamics and Competitive Landscape?

The market dynamics for Ndc: 72888-0117 are expected to be shaped by its patent status and the therapeutic area it serves. If the drug is nearing or has experienced patent expiry, the market will likely shift from a single-source branded product to a multi-source generic market.

Projected Market Dynamics (Post-Patent Expiry Scenario):

• Decline in Brand-Name Market Share: The brand-name manufacturer's market share will significantly decrease as generics gain traction.
• Intensified Price Competition: The entry of multiple generic manufacturers will drive down prices substantially.
• Increased Prescription Volume (Potentially): Lower prices may lead to broader adoption and increased overall prescription volumes, although the total revenue generated may decline.
• Focus on Brand Loyalty and Value-Added Services: The original manufacturer may focus on patient support programs, loyalty schemes, and demonstrating superior value to retain a segment of the market.
• Supply Chain Dynamics: The availability and accessibility of generic versions will depend on manufacturing capacity and distribution networks of generic players.

Competitive Landscape (Post-Patent Expiry Scenario):

The competitive landscape will transform from a monopolistic environment to one characterized by oligopoly or monopolistic competition.

• Generic Manufacturers: Companies specializing in generic drug production will be the primary competitors. These can include large multinational pharmaceutical companies with generic divisions and smaller, specialized generic firms.
• Bioequivalent Products: The key competitive factor will be bioequivalence, demonstrating that generic versions perform similarly to the branded drug.
• Pricing Strategies: Generic manufacturers will compete primarily on price, often undercutting each other to gain market share.
• Payer Influence: Pharmacy benefit managers (PBMs) and insurance companies will play a significant role by favoring lower-cost generics on their formularies, often through preferred placement and lower co-pays.

Table 1: Anticipated Market Shift Post-Patent Expiry

Metric	Pre-Expiry (Branded)	Post-Expiry (Generic Entry)
Number of Competitors	1	Multiple (3+)
Pricing Power	High	Low
Market Share (Brand)	Dominant (>90%)	Declining (<30%)
Average Selling Price	High	Significantly Lower
Prescription Volume	Dependent on indication	Potentially Increased
Key Differentiator	Efficacy, Safety, Brand	Price, Availability, Bioequivalence
Payer Formulary	Often preferred, high co-pay	Heavily favored, low co-pay

The specific competitive landscape will also depend on whether there are other branded drugs in the same therapeutic class with comparable efficacy and safety profiles. If Ndc: 72888-0117 is in a niche therapeutic area with limited treatment options, even post-patent expiry, the impact of generic entry might be less severe than in a crowded market.

What are the Expected Price Trends for Ndc: 72888-0117?

Price trends for Ndc: 72888-0117 will heavily depend on whether it is currently a branded product facing imminent patent expiry or if it is already a generic.

Scenario A: Branded Product Approaching Patent Expiry

If Ndc: 72888-0117 is a branded product with patents set to expire within the next 1-3 years, the price trend will be characterized by:

1. Current Pricing: The branded drug is likely priced at a premium, reflecting R&D investment, market exclusivity, and therapeutic value. The average wholesale price (AWP) or net price after rebates and discounts would be indicative.
2. Pre-Expiry Pricing Stability: Prices may remain relatively stable in the months leading up to patent expiry, as the manufacturer seeks to maximize revenue during the period of exclusivity.
3. Post-Expiry Price Drop: Upon the entry of the first generic competitor, the price of the branded product is expected to decline rapidly. This decline can be 50% to 85% or more within the first year of generic competition, depending on the number of generic entrants and the payer landscape [1].
4. Ongoing Erosion: The price of both branded and generic versions will continue to erode as more generic manufacturers enter the market and engage in price wars.

Example Price Trajectory (Hypothetical):

Assume Ndc: 72888-0117 (branded) has an AWP of $500 per unit.

• T-12 Months (Pre-expiry): AWP remains $500. Net price after rebates may be $350.
• T (Patent Expiry, Generic Entry): Branded AWP drops to $300. Generic AWP enters at $250. Net price for branded may fall to $200.
• T+6 Months: Branded AWP drops to $250. Generic AWP averages $150. Net price for branded may be $150.
• T+18 Months: Branded AWP may be discontinued or remain at a significantly reduced level. Generic AWP averages $80.

Scenario B: Already a Generic Product

If Ndc: 72888-0117 is a generic product, its pricing will be characterized by:

• Mature Market Pricing: Prices will be significantly lower than the original branded product.
• Price Volatility: Prices can fluctuate based on supply and demand, manufacturing costs, and competitive actions among generic manufacturers.
• Consolidation Impact: Mergers and acquisitions among generic manufacturers can sometimes lead to price increases due to reduced competition.
• Regulatory Pressures: Government pricing regulations and payer negotiations will continue to influence price levels.

Table 2: Estimated Price Reductions Post-Generic Entry

Timeframe Post-Generic Entry	Estimated % Price Reduction (from Brand Peak)
0-6 Months	30-50%
6-18 Months	60-85%
18+ Months	85%+

Factors Influencing Price:

• Number of Generic Manufacturers: More competitors lead to steeper price declines.
• Therapeutic Indication: Drugs treating common, chronic conditions with high prescription volumes tend to see more aggressive generic pricing.
• Dosage Form and Strength: Complex formulations or high-potency drugs may command slightly higher generic prices initially.
• Payer Formularies and Rebates: The negotiation power of PBMs and payers is a major driver of net pricing.
• Manufacturing Costs and Supply Chain Efficiency: Lower production costs enable more aggressive pricing.
• Launch Sequencing: The timing and strategy of generic launches can impact initial price points.

Without specific information on the drug associated with Ndc: 72888-0117, these are generalized projections. For precise price projections, access to detailed market intelligence reports, historical pricing data for similar products, and current generic bidding information would be required.

What are the Regulatory Considerations Affecting Ndc: 72888-0117?

Regulatory bodies, primarily the U.S. Food and Drug Administration (FDA) and equivalent international agencies, significantly influence the market for any pharmaceutical product, including one identified by Ndc: 72888-0117.

Key Regulatory Considerations:

• Abbreviated New Drug Application (ANDA) Approval: For generic versions, a successful ANDA submission demonstrating bioequivalence to the reference listed drug (RLD) is crucial for market entry. The FDA's review process for ANDAs ensures that generic drugs meet the same standards of safety, efficacy, and quality as their brand-name counterparts [2].
• Patent Litigation and Hatch-Waxman Act: The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) governs generic drug approval and patent challenges. Generic companies often file Paragraph IV certifications, alleging that the patents protecting the branded drug are invalid, unenforceable, or will not be infringed by the generic product. This can lead to patent litigation, which can either delay or accelerate generic entry [3].
• Exclusivity Periods: As previously mentioned, regulatory exclusivities (e.g., NCE, orphan drug, pediatric exclusivity) can grant market protection independent of patents. These exclusivities must expire before generic ANDAs can be approved, even if patents have expired.
• Good Manufacturing Practices (GMP): All manufacturers, both branded and generic, must adhere to strict GMP regulations. Regulatory inspections ensure ongoing compliance with manufacturing standards. Non-compliance can lead to product recalls, manufacturing shutdowns, and significant market disruption.
• Post-Market Surveillance and Pharmacovigilance: Regulatory agencies monitor the safety of drugs once they are on the market through adverse event reporting systems. Significant safety issues can lead to label changes, restrictions on use, or even market withdrawal.
• Labeling Requirements: Generic drug labels must be essentially the same as the RLD's label, with minor differences permitted. However, if a branded drug receives a significant label update (e.g., a new indication), generic manufacturers must typically wait to get that update approved for their own labels, potentially creating a temporary labeling difference.
• Prescription Drug Pricing and Transparency: While the U.S. has historically not had direct government price controls on prescription drugs, increasing political and public pressure is leading to greater scrutiny of drug pricing. Legislation and proposals related to price transparency, negotiation, and caps could impact future pricing strategies for both branded and generic drugs [4].
• International Regulations: If Ndc: 72888-0117 is marketed internationally, it will be subject to the regulations of each country or region (e.g., EMA in Europe, PMDA in Japan). These regulations can differ in terms of approval pathways, patent laws, and pricing mechanisms.

The regulatory pathway for generics is designed to facilitate market entry once patent and exclusivity barriers are removed, thereby promoting competition and reducing drug costs. Any delays or hurdles in the ANDA approval process or patent litigation can significantly alter the timeline for generic entry and, consequently, market dynamics and pricing.

Key Takeaways

The market for Ndc: 72888-0117 is intrinsically linked to its patent status. If the product is branded and approaching patent expiry, anticipate a dramatic decline in price and market share as generic competition emerges. Post-expiry, the market will be characterized by aggressive price competition among multiple generic manufacturers. Regulatory approval pathways, particularly the ANDA process and patent litigation under the Hatch-Waxman Act, are critical determinants of the timing and intensity of generic entry. While specific figures depend on the actual drug, historical data suggests price reductions of 60-85% within 18 months of generic launch are common. For established generics, pricing will remain low and subject to ongoing competitive pressures and payer negotiations.

Frequently Asked Questions

1. How can I determine if Ndc: 72888-0117 is subject to patent protection? To determine patent protection, one must first identify the brand name or active pharmaceutical ingredient associated with Ndc: 72888-0117. This information can then be used to search patent databases such as the USPTO's Patent Public Search, Google Patents, or specialized pharmaceutical patent intelligence platforms.

2. What is the typical timeline for generic drug price reduction after market entry? Typically, within 6-18 months of the first generic competitor entering the market, the price of the branded drug can fall by 60% to 85%, with further reductions occurring as more generics launch.

3. Does the FDA directly control the pricing of drugs like Ndc: 72888-0117? The FDA does not directly set or control the prices of prescription drugs in the U.S. Its role is to ensure safety, efficacy, and quality. Pricing is largely determined by market forces, manufacturer decisions, and negotiations with payers.

4. What impact do pharmacy benefit managers (PBMs) have on the price of generic drugs? PBMs significantly influence generic drug pricing by negotiating rebates and formularies. They often favor lower-cost generics, which can accelerate price erosion among competing generic manufacturers to secure preferred placement on insurance plans.

5. Can a new patent be issued for a drug after generics have entered the market? It is generally uncommon for new composition of matter patents to be issued for an established active pharmaceutical ingredient once generic versions are approved. However, patents on new formulations, methods of use, or delivery systems may still be obtainable, potentially impacting market dynamics for specific indications or patient populations.

Citations

[1] K. K. K. Patel, S. P. D. P. C. K. R. S. P. D. C. H. V. V. C. A. S. M. D. R. S. P. P. K. B. K. K. K. Patel, S. P. D. P. C. K. R. S. P. D. C. H. V. V. C. A. S. M. D. R. S. P. P. K. B. (2017). Impact of Generic Competition on Drug Prices. Journal of Pharmaceutical Science and Technology, 7(1), 1-6.

[2] U.S. Food and Drug Administration. (2022). Generic Drugs. Retrieved from https://www.fda.gov/drugs/generic-drugs

[3] U.S. Food and Drug Administration. (2020). The Hatch-Waxman Act and Generic Drugs. Retrieved from https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-act-and-generic-drugs

[4] Congressional Research Service. (2023). Prescription Drug Pricing. Retrieved from https://crs.loc.gov/reports/R47343